Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Ostend

29 clinical trials in Ostend, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ostend at a glance
29
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

29 trials in Ostend

Open in trial search

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Obesity+1

Recruiting

A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Recruiting

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Recruiting

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Colon cancer metastatic

Recruiting

Study Comparing Dostarlimab with CAPEOX and CAPEOX Alone for Patients with Untreated Stage III Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Hormone-refractory prostate cancer+2

Recruiting

Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Karolinska Institutet

Aortic valve replacement

Recruiting

Study on Lowering INR to Reduce Bleeding in Patients with Mechanical Aortic Valves Using Warfarin, Acenocoumarol, and Phenprocoumon

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Hamilton Health Sciences Corporation

Crohn's disease

Recruiting

Study on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:UZ Leuven

Endometrial cancer

Recruiting

Study on Durvalumab for Patients with High-Risk Endometrial Cancer After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Leiden University Medical Center

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Ostend

What the registry says about research in the country

01 Diseases [C] - Nutritional and Metabolic Diseases [C18]

In Oostende, current clinical research is centered on nutritional and metabolic diseases, with studies focused on improving outcomes for people living with obesity, overweight, and metabolic dysfunction-associated steatotic liver disease.

  • Evaluating new approaches for obesity management
  • Studying treatment options for overweight and related metabolic risk
  • Exploring therapies for metabolic dysfunction-associated steatotic liver disease
  • Aiming to improve cardiovascular, kidney, and liver-related health outcomes

The trials are designed to test whether emerging therapies can reduce serious complications and support better long-term disease control.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.